These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20447761)

  • 1. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.
    Lee CK; Wang S; Huang X; Ryder J; Liu B
    Cancer Lett; 2010 Oct; 296(2):233-40. PubMed ID: 20447761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
    Cai B; Lyu H; Huang J; Wang S; Lee CK; Gao C; Liu B
    Cancer Lett; 2013 Jul; 335(2):343-50. PubMed ID: 23459296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
    Wang B; Lyu H; Pei S; Song D; Ni J; Liu B
    Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.
    Ma J; Wang S; Zhao M; Deng XS; Lee CK; Yu XD; Liu B
    BMC Cancer; 2011 Jun; 11():255. PubMed ID: 21679466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
    Xiong T; Wei H; Chen X; Xiao H
    Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
    Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
    PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
    Lamottke B; Kaiser M; Mieth M; Heider U; Gao Z; Nikolova Z; Jensen MR; Sterz J; von Metzler I; Sezer O
    Eur J Haematol; 2012 May; 88(5):406-15. PubMed ID: 22309072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
    López-Iglesias AA; Herrero AB; Chesi M; San-Segundo L; González-Méndez L; Hernández-García S; Misiewicz-Krzeminska I; Quwaider D; Martín-Sánchez M; Primo D; Paíno T; Bergsagel PL; Mehrling T; González-Díaz M; San-Miguel JF; Mateos MV; Gutiérrez NC; Garayoa M; Ocio EM
    J Hematol Oncol; 2017 Jun; 10(1):127. PubMed ID: 28633670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
    Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
    Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
    Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
    Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
    Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
    Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
    Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
    Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC
    Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Apoptosis and re-expression of p16 gene in the myeloma cell line U266 induced by synergy of histone deacetylase inhibitor and demethylating agent].
    Du HL; Qi Y; Shi YJ; Bu DF; Wu SL
    Ai Zheng; 2002 Oct; 21(10):1057-61. PubMed ID: 12508642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.